ID 4453 - Kwas gamma-linolenowy

PL: Kwas gamma-linolenowy
EN: Gamma linolenic acid (GLA)
Pdf:

Oświadczenie (2)

1. Charakterystyka żywności / składnika

The food constituents that are the subject of the health claims are "gamma-linolenic acid (GLA; C18: 3n-6) provided by evening primrose oil and/or borage (starflower) oil", "gamma-linolenic acid", "evening primrose oil (Oenothera biennis) contains gamma-linolenic acid", "borage oil (GLA= gamma linolenic acid)", "oenothera biennis-evening primrose-seeds oil", "long chain omega 6 polyunsaturated fatty acid GLA (gamma-linolenic acid)", "Borago officinalis", and "GLA (example from Borago officinalis, primrose oil, black currant seed oil)".
In the context of the proposed health relationships, wordings, conditions of use, and the clarifications provided by Member States, the Panel assumes that the food constituent that is the subject of the health claims is gamma-linolenic acid (GLA).
GLA is a n-6 long-chain polyunsaturated fatty acid which is present in small amounts in a variety of foods of both plant and animal origin and which can also be synthesised in the human body from its precursor linoleic acid (LA). GLA is a well recognised nutrient and can be measured in foods by established methods. This evaluation applies to GLA from all sources.
The Panel considers that the food constituent, gamma-linolenic acid (GLA), which is the subject of the health claims, is sufficiently characterised.

2.1. Utrzymanie prawidłowego stężenia cholesterolu LDL we krwi (ID 2661, 4452, 4453)

The claimed effects are "reduces lipids due to gamma-linolenic acid (GLA)", "reduces cholesterol due to gamma-linolenic acid (GLA)" and "helps to keep normal blood cholesterol". The Panel assumes that the target population is the general population.
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to the maintenance of normal blood LDL-cholesterol concentrations.
Low-density lipoproteins (LDL) carry cholesterol from the liver to peripheral tissues, including the arteries. Elevated LDL-cholesterol, by convention >160 mg/dL (>4.1 mmol/L), may compromise the normal structure and function of the arteries.
The Panel considers that maintenance of normal blood LDL-cholesterol concentrations is a beneficial physiological effect.

3.1. Utrzymanie prawidłowego stężenia cholesterolu LDL we krwi (ID 2661, 4452, 4453)

A claim on gamma-linolenic acid and maintenance of normal blood cholesterol concentrations has already been assessed with an unfavourable outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2010).
The additional evidence that was provided to substantiate the claim reports on a three-month uncontrolled open label supplementation study addressing the effects of primrose oil consumption on blood lipids in 20 hyperlipidaemic subjects (Viikari and Lehtonen, 1986). The Panel considers that no conclusions can be drawn from this uncontrolled study for the scientific substantiation of the claimed effect.
The Panel considers that the references cited for this claim did not provide any additional evidence to change the outcome of the previous evaluation.

Warunki i możliwe ograniczenia stosowania oświadczenia